Literature DB >> 25448717

Interaction of 5-fluoro-5'-deoxyuridine with human serum albumin under physiological and non-physiological condition: a biophysical investigation.

Mohd Ishtikhar1, Gulam Rabbani1, Rizwan Hasan Khan2.   

Abstract

Uridine analogs 5'dFUrd (a cytotoxic metabolite of a prodrug capecitabine that enzymatically converted into 5'dFUrd) commonly used in the treatment of advanced human cancers, especially gastrointestinal tract, ovary, colorectal, breast cancers etc. Drugs/metabolites are transported in the blood by transporter proteins like human serum albumin (HSA). Here we investigate the interaction of 5'dFUrd to HSA by spectroscopic and calorimetric techniques at physiological (pH 7.4) and non-physiological (pH 9.0) conditions. The binding constant (Kb), enthalpy change (ΔH°), entropy change (ΔS°) and Gibbs free energy change (ΔG°) were also calculated under both conditions. The secondary structure of HSA showed greater alteration in helicity at physiological pH. ITC measurement reveals that HSA have high binding affinity at physiological pH as compares to non-physiological conditions. The thermostability of HSA alone as well of the HSA-drug complex was found to be higher at physiological pH. The binding study was also explored through molecular docking studies which revealed that 5'dFUrd was bound to subdomain IIA of Sudlow's site I through multiple mode of interaction. These results suggest that 5'dFUrd have high binding affinity at physiological condition or "N" isoform so lower drug concentrations are required in compare to non-physiological or "B" isoform of HSA to completely occupied the binding site of the protein.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-Fluoro-5′-deoxyuridine; Binding; Circular dichroism; Differential scanning calorimetry; Human serum albumin; Isothermal titration calorimetry

Mesh:

Substances:

Year:  2014        PMID: 25448717     DOI: 10.1016/j.colsurfb.2014.09.044

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

1.  Domain-specific interactions between MLN8237 and human serum albumin estimated by STD and WaterLOGSY NMR, ITC, spectroscopic, and docking techniques.

Authors:  Hongqin Yang; Jiuyang Liu; Yanmei Huang; Rui Gao; Bin Tang; Shanshan Li; Jiawei He; Hui Li
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

2.  Interaction study of monoisoamyl dimercaptosuccinic acid with bovine serum albumin using biophysical and molecular docking approaches.

Authors:  Ashima Thakur; Jayant Patwa; Suyash Pant; Abha Sharma; S J S Flora
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

3.  Biochemical and Biophysical Characterisation of the Hepatitis E Virus Guanine-7-Methyltransferase.

Authors:  Preeti Hooda; Mohd Ishtikhar; Shweta Saraswat; Pooja Bhatia; Deepali Mishra; Aditya Trivedi; Rajkumar Kulandaisamy; Soumya Aggarwal; Manoj Munde; Nemat Ali; Abdullah F AlAsmari; Mohd A Rauf; Krishna K Inampudi; Deepak Sehgal
Journal:  Molecules       Date:  2022-02-23       Impact factor: 4.411

4.  Rosin Surfactant QRMAE Can Be Utilized as an Amorphous Aggregate Inducer: A Case Study of Mammalian Serum Albumin.

Authors:  Mohd Ishtikhar; Tajjali Ilm Chandel; Aamir Ahmad; Mohd Sajid Ali; Hamad A Al-Lohadan; Ayman M Atta; Rizwan Hasan Khan
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

5.  Binding modes of environmental endocrine disruptors to human serum albumin: insights from STD-NMR, ITC, spectroscopic and molecular docking studies.

Authors:  Hongqin Yang; Yanmei Huang; Jiuyang Liu; Peixiao Tang; Qiaomei Sun; Xinnuo Xiong; Bin Tang; Jiawei He; Hui Li
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

Review 6.  Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal.

Authors:  Fahimeh Zare; Adriana Janeca; Seyyed M Jokar; Mónica Faria; Maria Clara Gonçalves
Journal:  Membranes (Basel)       Date:  2022-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.